Cargando…

Synchronous lung and gastric cancers successfully treated with carboplatin and pemetrexed: a case report

INTRODUCTION: Lung and gastric cancers are the first and second leading causes of death from cancer worldwide, and are especially prevalent in Eastern Asia. Relatively few reports are available in relation to the treatment and outcome of synchronous lung and gastric cancers, although there are incre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sato, Takashi, Tomaru, Koji, Koide, Tomoko, Masuda, Makoto, Yamamoto, Masaki, Miyazawa, Naoki, Inayama, Yoshiaki, Kaneko, Takeshi, Ishigatsubo, Yoshiaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441851/ https://www.ncbi.nlm.nih.gov/pubmed/22938085 http://dx.doi.org/10.1186/1752-1947-6-266

Ejemplares similares

The effectiveness of sputum pH analysis in the prediction of response to therapy in patients with pulmonary tuberculosis
por: Masuda, Makoto, et al.
Publicado: (2015)

Armadillo Repeat Containing 8α Binds to HRS and Promotes HRS Interaction with Ubiquitinated Proteins
por: Tomaru, Koji, et al.
Publicado: (2010)

Heterogeneity of the efficacy of the 23-valent pneumococcal polysaccharide vaccine caused by various underlying conditions of chronic pulmonary disease in older patients: prospective cohort study
por: Inoue, Satoshi, et al.
Publicado: (2011)

Successful Treatment with Pemetrexed, Carboplatin, and Bevacizumab for Platinum-Resistant Adenocarcinoma of the Lung
por: Wada, Sae, et al.
Publicado: (2012)

Evidence suggesting that oral corticosteroids increase mortality in stable chronic obstructive pulmonary disease
por: Horita, Nobuyuki, et al.
Publicado: (2014)

Statins reduce all-cause mortality in chronic obstructive pulmonary disease: a systematic review and meta-analysis of observational studies
por: Horita, Nobuyuki, et al.
Publicado: (2014)

Long-acting beta-agonists reduce mortality of patients with severe and very severe chronic obstructive pulmonary disease: a propensity score matching study
por: Horita, Nobuyuki, et al.
Publicado: (2013)

Suppressive oligodeoxynucleotides synergistically enhance antiproliferative effects of anticancer drugs in A549 human lung cancer cells
por: TAKAHASHI, RYOHEI, et al.
Publicado: (2012)

Carboplatin/pemetrexed: COVID-19 infection: 2 case reports
Publicado: (2021)

Carboplatin/pembrolizumab/pemetrexed: COVID-19 pneumonia: case report
Publicado: (2021)

Phase II study of pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab in Japanese patients with non-squamous non-small cell lung cancer
por: YOKOI, TAKASHI, et al.
Publicado: (2014)

Sinus arrhythmia caused by pemetrexed with carboplatin combination: A case report
por: Quan, Xianghua, et al.
Publicado: (2022)

Evaluation of calculating carboplatin dosage in carboplatin–pemetrexed therapy as the first‐line therapy for Chinese patients with advanced lung adenocarcinoma
por: Zhu, Yixiang, et al.
Publicado: (2018)

Slowly developing toxic epidermal necrolysis-like reaction associated with pemetrexed and carboplatin
por: Eichhoff, Gerhard
Publicado: (2020)

Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis
por: Hayashi, Toshinobu, et al.
Publicado: (2021)

Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
por: Patil, Vijay Maruti, et al.
Publicado: (2017)

Pathology of asthma
por: Kudo, Makoto, et al.
Publicado: (2013)

Validity of Weekly Administration of Carboplatin after Carboplatin-Induced SIADH: Two Case Reports and Literature Review
por: Fujitsuka, Suguru, et al.
Publicado: (2022)

Synchronous Primary Lung Adenocarcinoma and Hepatocellular Carcinoma Successfully Treated with a Combination of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel
por: Egawa, Takashi, et al.
Publicado: (2021)

Acute cerebral arterial embolism following pemetrexed and carboplatin treatment in non-small-cell lung cancer: A case report
por: TAKEDA, MASAYUKI, et al.
Publicado: (2013)

Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
por: Ceresoli, G L, et al.
Publicado: (2013)

Carboplatin-Pemetrexed in Treatment of Patients with Recurrent/Metastatic Cancers of the Head and Neck; Superior Outcomes in Oropharyngeal Primaries
por: Malhotra, Binu, et al.
Publicado: (2015)

Phase II study of carboplatin, pemetrexed, and bevacizumab in advanced nonsquamous non–small‐cell lung cancer
por: Laslett, Nicole F., et al.
Publicado: (2018)

PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer
por: Zinner, Ralph G., et al.
Publicado: (2015)

Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression
por: Cardona, Andrés Felipe, et al.
Publicado: (2016)

Carboplatin, pemetrexed, and pembrolizumab was effective for primary salivary gland‐type lung adenocarcinoma diagnosed due to esophageal stricture: A case report
por: Kawakado, Keita, et al.
Publicado: (2021)

65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer
por: Schuette, Wolfgang, et al.
Publicado: (2017)

Efficacy and safety of first-line pemetrexed plus carboplatin followed by single-agent pemetrexed maintenance in elderly Chinese patients with non-squamous non-small-cell lung cancer
por: Zhao, Xinmin, et al.
Publicado: (2017)

Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials
por: Ceresoli, G L, et al.
Publicado: (2008)

Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed–carboplatin chemotherapy
por: Noronha, Vanita, et al.
Publicado: (2017)

Immune Reactions in Behçet's Disease
por: Kaneko, Fumio, et al.
Publicado: (2014)

Effect of renal function on pemetrexed-induced haematotoxicity
por: Ando, Yosuke, et al.
Publicado: (2016)

A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)
por: Hayashi, Hidetoshi, et al.
Publicado: (2022)

Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients
por: Zhang, Guan-Zhong, et al.
Publicado: (2010)

Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies—results of a phase I dose-escalation study
por: Blais, Normand, et al.
Publicado: (2013)

Pemetrexed-carboplatin with intercalated icotinib in the treatment of patient with advanced EGFR wild-type lung adenocarcinoma: A case report
por: Xu, Tongpeng, et al.
Publicado: (2017)

Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices
por: Velcheti, Vamsidhar, et al.
Publicado: (2021)

Successful Chemotherapy with Carboplatin and S-1 for Thymic Carcinoma: A Case Report
por: Igawa, Satoshi, et al.
Publicado: (2013)

Evidence for a novel antioxidant function and isoform-specific regulation of the human p66Shc gene
por: Miyazawa, Masaki, et al.
Publicado: (2014)

Autoantigen TRIM21/Ro52 as a Possible Target for Treatment of Systemic Lupus Erythematosus
por: Yoshimi, Ryusuke, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_99hbtrqnguscvkh7ccr90sumbh